Monday, June 23, 2008

B.N. Manohar

"Currently we are waiting for DCGI (Drug Controller General of India) approval for conducting clinical trials for AMI (acute myocardial infarction) and CLI (critical limb ischemia). By 2010 we intend to come out with stem-cell-based drug which will be available off the shelf and be affordable too."

B.N. Manohar, President of Stempeutics Research Pvt Ltd

June 23, 1 pm
YouTube: B.N. Manohar

Manohar about plans

video

Manohar on the USP of Stempeutics


video

Manohar about Solomon Papaiah

video

Manohar on the stem cell myths
video



1 comment:

Murali said...

More...

Manohar has been associated with the Manipal Group since Jan 2002 and has taken up the role of President at Stempeutics in August 2007. Prior to this Manohar has worked as a Chief Executive, Manipal Universal Learning, handling on Line Assessment business, Engineering Twinning Program, Global Nursing Program, Vocational Education and E-content development. He also had a stint at the Group level (MEMG) as Chief Information Officer and Chief Executive – Strategic Projects.


Prior to Joining Manipal Group, Manohar has had long and successful stints at Wipro GE Medical Systems, Lucas TVS and W.S. Industries. Manohar has a rich domain expertise in strategy planning for various industry segments, Business Development, Process Re-engineering, Business System integration and leveraging IT Technology for service operations. Manohar has done his B.E. from Regional Engineering College, Trichy and M.E. from Guindy Engineering College, Chennai.
**
Stempeutics Research Pvt Ltd, Bangalore is the first company in India to commence clinical trials using adult stem cells. This initiative is in line with the company’s vision to make available safe, effective and affordable stem cell therapies.


The company has submitted for approval to DCGI for the conduct of clinical trials in Myocardial Infarction (MI) and Critical Limb Ischemia (CLI). These trials will be conducted in accordance to ICH-GCP standards adopting a randomized double blinded multicentric trial across leading hospitals in India. The clinical trial is aimed to make commercially available a cell based product for conditions where the current medical treatment is limited to management. This would be the first cell based product to be available in India meant to address the current medical needs of millions of patients waiting with a treatment hope - Regenerating hope


Stempeutics is in the forefront of stem cell research and therapy using bone marrow derived Mesenchymal (MSC’s) stem cells for the last 3 years. These cells have are less tumorgenic and have no ethical issues when compared to embryonic stem cells.


The state of art technology and facilities complemented with stem cell experts also makes the site c GMP compliant – this means the organization is committed to deliver quality and affordable cell based therapies. This further is endorsed by the certification and approval of the lab facility by the Indian Council of Medical Research (ICMR) for stem cell research and therapy.



Just a little about - Human mesenchymal stem cells (hMSC) are present as a rare population of cells in bone marrow, representing 0.001 to 0.01% of the nucleated cells, but they can rapidly grow in culture without loosing their stemness. The hMSC can be expanded in vitro more than 1 million fold and retain the ability to differentiate to several mesenchymal lineages. The hMSC, with their attributes of ease of isolation, high expansion potential, genetic stability, reproducible attributes from isolate to isolate and the ability to enhance repair in many vital tissues, have the potential to treat a variety of diseases. It has been shown that MSCs, when transplanted systemically, are able to migrate to sites of injury in animals. Stempeutics has already conducted animal toxicity studies in mice and have found that these cells are safe and free of any adverse effects.


The on –going stem cell research focus also provides immense scope to generate future medical solutions for various medical conditions – this only confirms to Stempeutics commitment to deliver ‘Bench to Bedside’ therapies to Regenerate Hope to millions of patients.
**
Source:
Vishnu Kumar
brand-comm
New # 7, old # 4, Seetha Nagar Main Road, Nungambakkam Chennai- 34
M: 9444888516 (O): 044- 28252450/51 Fax:91(044) 42634228
Visit: www.brand-comm.com